Table 1.
Patient characteristics before and after propensity score matching
| All cohort | Propensity Score Matched Cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| ASA | No ASA | % or mean difference | p value | ASA | No ASA | % or mean difference | p value | |
| N | 3291 | 17,350 | 3291 | 2885 | ||||
| Age, median [IQR] | 77.6 [70–85.2] | 66.9 [54.4–78.4] | + 10.7 | < 0.001 | 77.6 [70–85.2] | 79 [70.6–86.1] | − 1.4 | 0.003 |
| Gender (males), n (%) | 2053 (62.4) | 9826 (56.6) | + 5.8% | < 0.001 | 2053 (62.4) | 1704 (59.1) | + 3.3% | 0.008 |
|
Race, n (%) Caucasian Black Hispanic Asian Others |
3174 (96.4) 10 (0.3) 71 (2.2) 7 (0.2) 29 (0.9) |
15,292 (88.1) 105 (0.6) 1629 (9.4) 95 (0.5) 229 (1.3) |
+ 8.3% − 0.3% − 7.2% − 0.3% − 0.4% |
< 0.001 |
3174 (96.4) 10 (0.3) 71 (2.2) 7 (0.2) 29 (0.9) |
2782 (96.4) 9 (0.3) 68 (2.4) 7 (0.2) 29 (0.9) |
0 0 + 0.2% 0 0 |
0.859 |
| Days from onset to admission, median [IQR] | 5 [3–8] | 7 [4–9] | − 2 | < 0.001 | 5 [3–8] | 5 [3–8] | 0 | 0.647 |
| BMI, median [IQR] | 28.6 [25.4–32] | 28.5 [25.3–32.1] | + 0.1 | 0.793 | 28.6 [25.4–32] | 28.5 [25.3–32] | + 0.1 | 0.653 |
|
Smoking behavior, n (%) Never smoker Former smoker Current smoker |
1912 (58.1) 1220 (37.1) 159 (4.8) |
12,460 (71.8) 4055 (23.4) 834 (4.8) |
− 13.7% + 13.7% 0 |
< 0.001 |
1912 (58.1) 1220 (37.1) 159 (4.8) |
1805 (62.6) 925 (32.1) 155 (5.4) |
− 4.5% + 5% − 0.6% |
< 0.001 |
|
Degree of dependency, n (%) None or mild Moderate Severe |
2340 (71.1) 532 (16.2) 419 (12.7) |
14,847 (85.6) 1419 (8.2) 1084 (6.2) |
− 14.5% + 8% + 6.5% |
< 0.001 |
2340 (71.1) 532 (16.2) 419 (12.7) |
2021 (70.1) 468 (16.2) 396 (13.7) |
+ 1% 0 − 1% |
0.498 |
| Arterial hypertension, n (%) | 2599 (79) | 8109 (46.7) | + 32.3% | < 0.001 | 2599 (79) | 2260 (78.3) | + 0.7% | 0.542 |
| Dyslipidemia, n (%) | 2140 (65) | 6046 (34.8) | + 30.2% | < 0.001 | 2140 (65) | 1790 (62) | + 3% | 0.015 |
| Diabetes mellitus, n (%) | 1235 (37.5) | 3000 (17.3) | + 20.2% | < 0.001 | 1235 (37.5) | 1021 (35.4) | + 2.1% | 0.082 |
| Atrial fibrillation, n (%) | 283 (8.6) | 1941 (11.2) | − 2.6% | < 0.001 | 283 (8.6) | 322 (11.2) | − 2.6% | 0.001 |
| Ischemic cardiopathy, n (%) | 953 (29) | 665 (3.8) | + 25.2% | < 0.001 | 953 (29) | 538 (18.6) | + 10.4% | < 0.001 |
| Cerebrovascular disease, n (%) | 662 (20.1) | 847 (4.9) | + 15.2% | < 0.001 | 662 (20.1) | 524 (18.2) | + 1.9% | 0.052 |
| Peripheral arterial disease, n (%) | 402 (12.2) | 471 (2.7) | + 9.5% | < 0.001 | 402 (12.2) | 275 (9.5) | + 2.7% | 0.001 |
| Dementia, n (%) | 567 (17.2) | 1,459 (8.4) | + 8.8% | < 0.001 | 567 (17.2) | 521 (18.1) | − 0.9% | 0.393 |
| Chronic heart failure, n (%) | 434 (13.2) | 946 (5.5) | + 7.7% | < 0.001 | 434 (13.2) | 338 (11.7) | + 1.5% | 0.081 |
| Chronic liver disease, n (%) | 124 (3.8) | 578 (3.3) | + 0.5% | 0.205 | 124 (3.8) | 133 (4.6) | − 0.8% | 0.098 |
| Severe chronic renal failure, n (%) | 390 (11.9) | 816 (4.7) | + 7.2% | < 0.001 | 390 (11.9) | 312 (10.8) | + 1.1% | 0.201 |
| Cancer, n (%) | 372 (11.3) | 1566 (9) | + 2.3% | < 0.001 | 372 (11.3) | 353 (12.2) | − 0.9% | 0.256 |
| COPD, n (%) | 371 (11.3) | 1029 (5.9) | + 5.4% | < 0.001 | 371 (11.3) | 317 (11) | + 0.3% | 0.722 |
| Asthma, n (%) | 195 (5.9) | 1257 (7.2) | − 1.3% | 0.007 | 195 (5.9) | 188 (6.5) | − 0.6% | 0.336 |
| OSAS, n (%) | 271 (8.2) | 966 (5.6) | + 2.6% | < 0.001 | 271 (8.2) | 222 (7.7) | + 0.5% | 0.435 |
| Charlson index median [IQR] | 2 [1–3] | 0 [0–2] | + 2 | < 0.001 | 2 [1–3] | 1 [1–3] | + 1 | < 0.001 |
ASA Acetylsalicylic acid, BMI body mass index, IQR interquartile range, COPD chronic obstructive pulmonary disease, OSAS obstructive sleep apnea syndrome, Severe chronic renal failure: Creatinine > 300 mg/dl or dialysis